Omeros' (OMER) "Buy" Rating Reaffirmed at D. Boral Capital

Omeros (NASDAQ:OMER - Get Free Report)'s stock had its "buy" rating restated by equities researchers at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They currently have a $36.00 target price on the biopharmaceutical company's stock. D. Boral Capital's target price points to a potential upside of 467.82% from the company's previous close.

A number of other research analysts have also issued reports on OMER. StockNews.com lowered shares of Omeros from a "hold" rating to a "sell" rating in a research report on Wednesday, April 9th. Needham & Company LLC restated a "hold" rating on shares of Omeros in a research report on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $22.50.

Omeros Trading Down 6.9 %

Shares of NASDAQ OMER opened at $6.34 on Wednesday. The business's 50 day moving average is $7.55 and its 200-day moving average is $8.11. The firm has a market cap of $369.66 million, a P/E ratio of -2.74 and a beta of 2.42. Omeros has a 1-year low of $3.00 and a 1-year high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last posted its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.71) by $0.08. During the same period last year, the company posted ($0.15) EPS. Analysts forecast that Omeros will post -3.09 EPS for the current year.

Institutional Trading of Omeros

Hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC boosted its holdings in shares of Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company's stock valued at $376,000 after acquiring an additional 51,873 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Omeros during the fourth quarter valued at about $46,000. Cerity Partners LLC grew its holdings in shares of Omeros by 9.9% during the fourth quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock worth $286,000 after purchasing an additional 2,600 shares during the last quarter. New York State Common Retirement Fund grew its holdings in shares of Omeros by 245.4% during the fourth quarter. New York State Common Retirement Fund now owns 17,313 shares of the biopharmaceutical company's stock worth $171,000 after purchasing an additional 12,300 shares during the last quarter. Finally, Franklin Resources Inc. acquired a new position in shares of Omeros in the fourth quarter valued at approximately $130,000. Institutional investors and hedge funds own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.